Angiotensin-II-directed glomerulosa cell function in fetal adrenal cells.
These studies were undertaken to examine the role of angiotensin II (A-II) in the regulation of adrenal glomerulosa cell differentiation. We were interested particularly in the ability of A-II to support aldosterone production in fetal adrenal cells. Many in vitro studies on acute A-II stimulation of aldosterone synthesis in adrenocortical cells have been documented. However, it is the long-term modification of steroid-metabolizing enzyme expression that leads to the formation and release of specific adrenal steroids. Herein, we used primary cultures of fetal bovine adrenal (FBA) cells to examine the effects of A-II on aldosterone production and the expression of aldosterone synthase cytochrome P450 (P450c18). A-II treatment caused the primary cultures to maintain glomerulosa cell functions. Cells treated for 3 days with A-II increased aldosterone production by 10-fold. A-II stimulation of aldosterone production occurred rapidly (within 30 min) and in a dose-dependent manner. In addition, A-II enhanced the activity of P450c18, the enzyme responsible for conversion of corticosterone to aldosterone. A-II also suppressed ACTH-promoted cortisol production, while increasing ACTH-stimulated release of aldosterone. It appears that these effects of chronic treatment with A-II were mediated through an A-II type 1 (AT(1)) receptor since the AT(1) receptor antagonist, Dup753, blocked aldosterone production and the increased P450c18 activity. Receptor binding studies suggest that FBA cells possess approx. 110,000 AT(1) binding sites/cell with K(d) = 1.8 × 10(-9) M. Via AT(1) receptors, A-II was able to stimulate both inositol phosphates and cAMP production. The stimulation of cAMP production, however, was much less than seen following ACTH treatment. These data give support to the hypothesis that A-II is involved in the differentiation of fetal adrenal cells into glomerulosa cells. This process appears to be mediated through regulation of steroid-metabolizing enzyme expression and the activation of steroid production.
Department of Obstetrics & Gynecology, The Green Center for Reproductive Biology Sciences, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 72535-9032, USA.
W E
WE
Rainey
I M
IM
Bird
J I
JI
Mason
D000311:Adrenal Glands / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D000450:Aldosterone / Q000378:metabolism*; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000378:metabolism*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D002417:Cattle; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D003366:Cosyntropin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D019405:Cytochrome P-450 CYP11B2 / Q000378:metabolism*; D015536:Down-Regulation / Q000187:drug effects; D006854:Hydrocortisone / Q000378:metabolism; D007295:Inositol Phosphates / Q000378:metabolism; D007700:Kinetics; D054801:Phosphoinositide Phospholipase C / Q000378:metabolism; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D015290:Second Messenger Systems / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects; D015384:Zona Glomerulosa / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*
D047228:Angiotensin II Type 1 Receptor Blockers; D007295:Inositol Phosphates; D044140:Receptor, Angiotensin, Type 1; D000804:Angiotensin II; D003366:Cosyntropin; D000450:Aldosterone; D000242:Cyclic AMP; D019405:Cytochrome P-450 CYP11B2; D054801:Phosphoinositide Phospholipase C; D006854:Hydrocortisone